Deals in Depth: May 2009
Top Tier Biotechs, as opposed to Big Pharma, featured as the prominent dealmakers with Celgene standing out thanks to its $540 million license to GlobeImmune's cancer programs. In M&As generics grabbed the attention of Novartis, which paid $1.2bn for Ebewe Pharma; meanwhile Covidien's $470 million takeover of Vnus expands its presence in the vascular market. The $1.2bn in biopharma financing was way up versus last month, but device fund-raising didn't fare as well, dropping 61%.
You may also be interested in...
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.
OTC marketing news from Germany: Bayer’s Talcid Liquid returns to pharmacy shelves, Stada extends its successful Probielle probiotics range and Dr Kade adds “gel” version of Riopan.
Perrigo is investing to grow its reinvigorated International consumer health business by acquiring three OTC skin-care brands from Sanofi.